Compare GSK plc (GSK) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nasdaq Inc — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while Nasdaq Inc trades at $92.91 (market cap $51.67B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | NDAQ | |
|---|---|---|
Market Cap | $101.34B | $51.67B |
Sector | Health | Financials |
52-Week High | $61.18 | $100.98 |
52-Week Low | $36.20 | $76.85 |
Enterprise Value | $121.95B | $58.73B |
Dividend Yield | 3.49% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Nasdaq (NDAQ) is trading at $88.01, down 1.35% on the day, with a bullish technical signal supported by moving averages. Fundamentally, the company reported strong revenue growth to $8.26B in 2025 and has consistently beaten earnings estimates, with a robust net income margin of 23.03%. Recent news highlights its core business activity, including new listings and market volume reports.
The outlook is positive, supported by strong analyst consensus and a price target implying ~20% upside. Key opportunities include sustained earnings growth and market leadership, while risks involve execution of strategic investments and sensitivity to capital market activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
